{"disease":{"id":"advanced-nsclc","name":"advanced nsclc"},"drugs":{"marketed":[{"drug_id":"osimertinib","indication_name":"First-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, in combination with pemetrexed and platinum-based chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"osimertinib","indication_name":"Treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"datopotamab-deruxtecan","indication_name":"Locally Advanced or Metastatic EGFR-Mutated NSCLC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DATOPOTAMAB DERUXTECAN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"ensartinib","indication_name":"ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ensacove","generic_name":"ENSARTINIB","company_name":"Xcovery","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Ensartinib works by inhibiting a specific protein that drives the growth of cancer cells."},{"drug_id":"deruxtecan","indication_name":"Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Datroway","generic_name":"DERUXTECAN","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Deruxtecan works by binding to and inhibiting the growth of cancer cells."},{"drug_id":"telisotuzumab","indication_name":"locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."},{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."},{"drug_id":"taletrectinib","indication_name":"locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibtrozi","generic_name":"TALETRECTINIB","company_name":"Nuvation","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Ibtrozi works by blocking the ROS1 protein, which is a genetic mutation found in some lung cancer cells."},{"drug_id":"pemetrexed-disodium","indication_name":"Locally Advanced or Metastatic Non-Squamous NSCLC - Initial Treatment with Cisplatin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PEMETREXED DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"sevabertinib","indication_name":"Locally advanced or metastatic non-squamous NSCLC with HER2 TKD mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SEVABERTINIB","company_name":"","drug_phase":"marketed","molecular_target":"HER2, EGFR","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Sevabertinib inhibits HER2 and EGFR phosphorylation, blocking downstream signaling and cancer cell proliferation."}],"pipeline":[{"drug_id":"bevacizumab-eu","indication_name":"Advanced Non-squamous NSCLC","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab-EU","generic_name":"bevacizumab-eu","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 we","quality_score":0,"revenue":null,"mechanism":"15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 we"},{"drug_id":"pf-06439535-cn","indication_name":"Advanced non-squamous non-small-cell lung cancer (NSCLC)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06439535 (CN)","generic_name":"pf-06439535-cn","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Not publicly disclosed; presumed to be VEGF pathway or related angiogenic target based on clinical trial design","drug_class":"Selective pathway inhibitor; presumed anti-angiogenic agent","quality_score":null,"revenue":null,"mechanism":"Selective inhibitor blocking proteins that drive abnormal cell growth and division in cancer cells."}],"offLabel":[],"totalMarketed":10,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT06686602","title":"A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":13759,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT05887011","title":"CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05339568","title":"Patient's Whole Process Follow-up Management(HOPE-1)","phase":"","overall_status":"RECRUITING","enrollment_count":1268,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT02991274","title":"ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory","phase":"","overall_status":"COMPLETED","enrollment_count":897,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07485179","title":"Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":770,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT03037086","title":"Asia PDL1 Study Among NSCLC Patients","phase":"","overall_status":"COMPLETED","enrollment_count":658,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05990127","title":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":642,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT06735391","title":"A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":516,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT07150598","title":"Immune-Marker Platform for Patients With Advanced Lung Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT07524257","title":"ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":494,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT05581004","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT07259226","title":"Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT06380348","title":"JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":398,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT06545331","title":"Study of XB010 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":396,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06927986","title":"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"CSPC Megalith Biopharmaceutical Co.,Ltd.","has_results":false},{"nct_id":"NCT05435248","title":"Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":354,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04129502","title":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":354,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05767892","title":"YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":350,"lead_sponsor_name":"Suzhou Puhe Pharmaceutical Technology Co., LTD","has_results":false},{"nct_id":"NCT07224971","title":"Impact of Circadian Rhythm on Immunotherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Liza Villaruz, MD","has_results":false},{"nct_id":"NCT04303780","title":"Study to Compare AMG 510 \"Proposed INN Sotorasib\" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":345,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04143607","title":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":337,"lead_sponsor_name":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02864992","title":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":337,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT02740985","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT04207775","title":"Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07491211","title":"Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07109531","title":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":286,"lead_sponsor_name":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06758557","title":"A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":282,"lead_sponsor_name":"Huabo Biopharm Co., Ltd.","has_results":false},{"nct_id":"NCT05014815","title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT05753722","title":"A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"Incendia Therapeutics","has_results":false},{"nct_id":"NCT07274813","title":"A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":254,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT07223047","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07058519","title":"A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT03596866","title":"A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03074175","title":"Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01)","phase":"NA","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Xinqiao Hospital of Chongqing","has_results":false},{"nct_id":"NCT07171606","title":"A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Shenyang Sunshine Pharmaceutical Co., LTD.","has_results":false},{"nct_id":"NCT06461156","title":"A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":230,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03114319","title":"Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05967689","title":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false},{"nct_id":"NCT03452592","title":"Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":220,"lead_sponsor_name":"Allist Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03457337","title":"S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT06635824","title":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":191,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT00369070","title":"A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":186,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05219162","title":"Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06784193","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05933265","title":"Study of LP-184 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Lantern Pharma Inc.","has_results":false},{"nct_id":"NCT06391944","title":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":161,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}